CUE: Cue Biopharma, Inc. insider trading, 5% holders and institutional ownership
From public SEC filings: open-market insider purchases and sales (Form 4, last 180 days), holders of 5% or more (Schedules 13D and 13G) and institutional ownership (Form 13F). Insider and 5% data delayed 48 hours.
Insider trading
0 open-market buys totaling - and 4 sales totaling $389K in the last 180 days.
Insider sales
| Trade date | Insider | Role | Value | 10b5-1 plan |
|---|---|---|---|---|
| 2026-10-12 | Meluzio Michael Vincent | Officer | $32K | |
| 2026-10-12 | Lin Shao-Lee | CEO | $275K | |
| 2026-10-12 | Lin Shao-Lee | CEO | $30K | |
| 2026-10-12 | Ray Sumita | Officer | $52K |
Activist and 5% holders
| Filed | What | Holder | Stake | Change | Filing |
|---|---|---|---|---|---|
| 2026-10-08 | 13G amendment | Mark E. Strome | 8.50% | SEC | |
| 2026-08-21 | New 13D stake | Shao-Lee Lin | 6.20% | SEC | |
| 2026-08-14 | New 13G stake | DRIEHAUS CAPITAL MANAGEMENT LLC | 6.96% | SEC |
Get new insider and activist filings the morning after: daily alerts. Not investment advice.